Whitepapers

How are sponsors empowering sites to reach their full potential in 2021?

Automating study start-up enables faster site activation, better collaboration with study partners, and more informed decision-making. That’s why sponsors and contract research organizations (CROs) are turning to technology specifically designed to manage the intricacies of study start-up.

Learn how you can improve cost and process efficiencies and make it easier for pharmacovigilance teams to perform advanced tasks.

Read this white paper on navigating the complexities of today’s increasingly complicated clinical trials. Consider the services your study needs for success.

Every successful clinical trial must protect patients while collecting complete, accurate data that supports evaluation of the safety and effectiveness of the drug or device. Here’s a closer look at why data and safety managers are so important to a clinical trial, what can go wrong when they aren’t aligned and how to improve collaboration between them.

Discover how a small pharmaceutical company leveraged unified visualizations and reporting into study data to save $50M in study costs and months in development time.

Insmed had a late-breaking strategy change that challenged their timelines. Learn how they incorporated significant protocol changes and still hit their FPI deadline.

Which new developments can help jump-start breakthroughs in immuno-oncology research? Understand the key scientific drivers, read peer-reviewed research, and get actionable ideas that can spur innovation in this must-read paper for clinical leaders.

In the wake of COVID-19, clinical research sites are in dire need of extra resources to help run their clinical trials. By utilizing qualified, experienced WCG Clinical Research Coordinators (CRCs), these professionals can help overburdened study teams get tasks done, and get them done with efficiency and precision.

Discover how a small pharmaceutical company leveraged unified visualizations and reporting into study data to save $50M in study costs and months in development time.

Private practices tap into an industry investing more than $15 billion annually in the USA. These five recommendations help practices capitalize on potential benefits.

Cerba Research initiated custom kit building & distribution for an infectious disease study, during the COVID-19 pandemic, in 10 days. A typical timeline is 8 weeks.

Find out how traditional trial modalities have evolved to participant-centric virtual platforms and how to best engage your IRB in this Advarra-Science 37 collaboration.

Incorporating genetics into rare disease clinical trials is both effective and challenging. This white paper offers strategies for successful implementation.

Cerba Research initiated custom kit building & distribution for an infectious disease study, during the COVID-19 pandemic, in 10 days. A typical timeline is 8 weeks.

Decentralized or hybrid trial models have not been widely adopted in clinical research until now. See how COVID-19 is ushering in a new era of clinical research.

With new technology and groundbreaking medical devices being introduced every week, there’s never been a more exciting time to be involved in clinical research. Even during the coronavirus pandemic, the pace of innovation has only accelerated. 

This article discusses strategies for finding the best cultural fit for a biopharmaceutical company, and the positive impact it has on implementing a successful FSP model, driving efficiency and continuity.

To attract research opportunities, organizations must start studies quickly, deliver promised enrollment, and produce quality research data. Discover ways to streamline and fortify your research administration program in this paper.

While the FDA has issued guidance to help sponsors, investigators and IRBs decide on the best ways to protect patients while keeping their trial moving, the decision is ultimately up to each individual research team. IMARC has assisted research teams with remote monitoring, auditing and other activities for years. More recently, our team helped one company transition to an entirely remote clinical trial. We wanted to share this example to show it can be done, under certain circumstances and with careful consideration.